Illustrative

Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData

Fierce Pharma·Jan 2

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Eli Lilly's Zepbound is expected to surpass Novo Nordisk's Wegovy in the obesity market. The two companies are competing in the GLP-1 market, with some reports suggesting Lilly is pulling ahead, potentially dominating the market. The outcome is not certain, with some outlets framing the competition as an ongoing contest between the two companies.

Full coverage

Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test

BioSpace·Feb 23

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

CNBC·Feb 4

Obesity market sales potential tightens as Novo and Lilly enter new era

Reuters·Feb 2

Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may dominate the oral market eventually

drugdiscoverytrends.com·Jan 5

How Eli Lilly became the new king of GLP-1s

Axios·Oct 21

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

24/7 Wall St.·Feb 4

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?

The Motley Fool·Jan 13

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

The Globe and Mail·May 1

View original report at Fierce Pharma ↗

Fetching the latest headlines…